Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.36 |
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
| ▸ | RORC | P51449 | 9/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17660751 | 0.88 | DRD2 (0.40) | DRD2DRD1DRD3MTNR1AMTNR1B | |
| SCHEMBL31137696 | 0.76 | DRD2 (0.43) | DRD2DRD1DRD3MTNR1AMTNR1B | |
| SCHEMBL17656945 | 0.75 | RORC (0.31) | DRD2DRD1RORC | |
| SCHEMBL924440 | 0.75 | RORC (0.37) | DRD2DRD1MTNR1AMTNR1BHTR2C | |
| SCHEMBL31397659 | 0.75 | RORC (0.37) | DRD2DRD1MTNR1AMTNR1BHTR2C | |
| SCHEMBL28447625 | 0.71 | DRD2 (0.41) | DRD2DRD1DRD3MTNR1AMTNR1B | |
| SCHEMBL1769807 | 0.70 | ALDH1A1 (0.39) | DRD2DRD1DRD3MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL31136315 | 0.70 | DRD2 (0.40) | DRD2DRD1DRD3MTNR1AMTNR1B | |
| SCHEMBL12891719 | 0.66 | DRD2 (0.40) | DRD2DRD1DRD3HTR2CDDB1 | |
| SCHEMBL12891720 | 0.66 | DRD2 (0.40) | DRD2DRD1DRD3HTR2CDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160096808-A1 | METHODS OF RESOLVING RACEMIC MIXTURE TO OBTAIN (-)-HUPERZINE A | AMPHASTAR NANJING PHARMACEUTICALS INC. (CN) | 2016-04-07 | — | — | US | disclosed |
| WO-2016054286-A1 | METHODS OF RESOLVING RACEMIC MIXTURE TO OBTAIN (-)-HUPERZINE A | AMPHASTAR PHARMACEUTICALS, INC. (US) | 2016-04-07 | — | — | WO | disclosed |
| US-20160096808-A1 | METHODS OF RESOLVING RACEMIC MIXTURE TO OBTAIN (-)-HUPERZINE A | AMPHASTAR NANJING PHARMACEUTICALS INC. (CN) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096808-A1 | METHODS OF RESOLVING RACEMIC MIXTURE TO OBTAIN (-)-HUPERZINE A | ADH1C, GALE, UGT8 | DRD2 1155/4885DRD1 1140/4885DRD3 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.